Menu
Recruiting NCT06930976

Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells

No phase Interventional Glucose Metabolism Isotope Labeling Immune System and Related Disorders

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: 13C6-Glucose.
Who it may be relevant to
Registry conditions: Glucose, Metabolism, Isotope Labeling, Immune System and Related Disorders. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.

Interventions

  • Drug 13C6-Glucose
    Compounded as 5% 13C6-Glucose in sterile water given IV over 2-4 hours as a split bolus and infusion

Primary outcome measures

  • 13C6-glucose uptake in immune cells [Time frame: Up to 4 hours]

Eligibility criteria

Inclusion criteria

  • Adults aged 18 or older

Exclusion criteria

  • Pregnant
  • Prisoner or in police custody
  • Uncontrolled hyperglycemia/diabetes
  • Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500cc in an 8 week period
  • Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, that might interfere with the study objectives
  • Any reason which, in the opinion of the study investigator, adds additional risk to the participant

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

United States · 1 center
  • Vanderbilt University Medical Center — Nashville

Identifiers

NCT: NCT06930976 · 241348

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗